Therapeutic compounds
AssigneesCancer Research Technology Limited, Pfizer Inc.
InventorsThomas Helleday, Nicola Curtin
Life of this patent
Estimating the term…
Abstract
The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
Claims15
A method for treating cancer in a mammal, wherein the cancer is of a type that is caused by a genetic defect in a gene that mediates homologous recombination and is selected from the group consisting of cancer of the:
- breast, lung, colon, pancreas, stomach, ovary, cervix, breast, prostate, bone, brain, and skin, the gene that mediates homologous recombination being selected from the group consisting of:
- XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51, RAD51C, RAD51D, DMC1, XRCCR, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NB51, WRN, BLM KU70, KU80, ATM, ATR CHK1, CHK2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9 and combinations thereof, the method comprising:
- selecting the mammal having said genetic defect;
- and
- administering to the mammal a compound selected from the group consisting of a compound of the formula I, formula II and formula III:
- or a pharmaceutically acceptable salt thereof.
A method for inducing apoptosis of cells defective in a gene that mediates homologous recombination, the cells being cancer cells selected from the group consisting of cancer cells of the:
- breast, lung, colon, pancreas, stomach, ovary, cervix, breast, prostate, bone, brain, and skin, the gene that mediates homologous recombination being selected from the group consisting of XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51β, RAD51C, RAD51D, DMC1, XRCCR, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NB51, WRN, BLM KU70, KU80, ATM, ATR CHK1, CHK2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9 and combinations thereof, the method comprising:
- selecting the cancer cells having said genetic defect;
- and
- administering to the cancer cells a compound selected from the group consisting of a compound of the formula I, formula II and formula III:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.